Close Menu

biomarker discovery

With $50 million from Japanese firm NEC, biomedical software startup BostonGene seeks to assess patients' "immune fitness" in the quest for better therapies.

The companies are using Strata's biomarker technology to identify genomic subpopulations of cancer patients who respond to Arcus' investigational immunotherapy drug.

Using RNA sequence data from the Cancer Genome Atlas and the Chinese Glioma Genome Atlas, researchers identified six genes with expression ties to overall survival.

The new multinational consortium, backed by the EU and Canada, seeks to improve understanding of immune responses and uncover new therapeutic targets.

The new, multinational iReceptor Plus Consortium will develop a platform for sharing of AIRR-seq data to advance immunotherapy and precision medicine.

Pages